Worldwide Rare Kidney Diseases Industry Report to 2035 - Key Market Trends and Forecasts - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Rare Kidney Diseases Market by Target Indications, Type of Molecule, Route of Administration and Key Geographies: Industry Trends and Global Forecast, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study of the current market landscape and the likely future potential associated with the rare kidney diseases market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
The term rare kidney diseases (RKD) represents around 150 different indications. It is worth highlighting that the prevalence rate of rare kidney diseases is estimated to be 60-80 per 100,000 cases / individuals in the US and Europe. Despite their relatively low prevalence, these set of indications are believed to be one of the leading causes of renal diseases, along with diabetes and other rare genetic kidney disease.
The low incidence rate of such disorders, coupled to the lack of awareness among the general population, often leads to late or erroneous diagnosis.
This, in turn, enables suboptimal therapeutic management, as well as compromised long-term outcomes. The aforementioned factors are some of the key reasons that are believed to be responsible for high mortality rates and severe compromise on chance of survival of a patient suffering with rare kidney diseases.
It is worth mentioning that, post the onset of the COVID-19 pandemic, the treatment of patients affected with rare kidney diseases became even more challenging. This can be primarily attributed to the fact that the current treatment options for such indications are heavily reliant on regular patient visits to the hospitals or medical centers.
Consequently, during the pandemic, a 30% increase in mortality rate was observed in affected patients. This increase in mortality has compelled players engaged in the pharmaceutical domain to undertake necessary research initiatives in order to identify novel drugs that can efficiently treat rare kidney diseases.
Given the complexity associated with conventional treatment options, such as dialysis, kidney transplant and biopsy, drug developers engaged in this domain have shifted their focus towards the development of drugs that can target a myriad of rare kidney diseases.
It is worth highlighting that, since 2020, over seven drugs have received marketing approval for the treatment of rare kidney diseases; these are (in reverse chronological order of approval) Galafold (Fabry disease, European Medicines Agency (EMA), 2021), LupkynisT (Lupus Nephritis (LN), United States Food and Drug Administration (USFDA), 2021), SibnayalT (distal Renal Tubular Acidosis (dRTA), EMA, 2021), Tarpeyo (Immunoglobulin A Nephropathy (IgAN), USFDA, 2021), Benlysta (LN, USFDA, 2020), Cystadrops (Cystinosis, USFDA, 2020), and Ultomiris (Atypical Hemolytic Uremic Syndrome (aHUS), Japan, 2020).
Further, more than 90 candidates targeting rare kidney diseases are currently under clinical investigation, while several novel leads are being evaluated in early stages of development. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. In fact, over USD 4.5 billion has been invested in this domain since 2020. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.
- Achillion Pharmaceuticals
- Aduro Biotech
- Aevitas Therapeutics (A subsidiary of Fortress Biotech)
- Alexion Pharmaceuticals (A subsidiary of AstraZeneca)
- Alnylam Pharmaceuticals
- Amicus Therapeutics
- Amyndas Pharmaceuticals
- Anelixis Therapeutics (Acquired by Eledon Pharmaceuticals)
- Apellis Pharmaceuticals
- Apple Tree Partners
- Arrowhead Pharmaceuticals
- ARYA Sciences Acquisition
- Asahi Kasei Pharma
- Astellas Pharma
- Aurinia Pharmaceuticals
- Beam Therapeutics
- BioCryst Pharmaceuticals
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Calliditas Therapeutics
- CHIESI Farmaceutici
- Chinook Therapeutics
- Cian Healthcare
- Cormorant Asset Management
- Dicerna Pharmaceuticals
- EcoR1 Capital
- Eledon Pharmaceuticals (Formerly known as Novus Therapeutics)
- Ember Therapeutics
- And Many More Companies!
Key Questions Answered
- Who are the leading players engaged in the development of drugs targeting rare kidney diseases?
- Which are the key drugs being developed across early and late stages of development?
- Who are the key players providing services related to kidney care?
- Which are the key indications targeted by drugs indicated for rare kidney diseases?
- What type of partnership models are commonly adopted by stakeholders engaged in this domain?
- Who are the key investors in the domain?
- Which regions have emerged as the key hubs for conducting clinical studies focused on rare kidney diseases?
- How is the current and future market opportunity likely to be distributed across key market segments?
Key Topics Covered:
2. EXECUTIVE SUMMARY
4. MARKET LANDSCAPE
5. DRUG PROFILES
6. COMPANY COMPETITIVENESS ANALYSIS
7. PARTNERSHIPS AND COLLABORATIONS
8. FUNDING AND INVESTMENTS
9. CLINICAL TRIAL ANALYSIS
10. MARKET FORECAST
11. CLINICAL COMMERCIAL ATTRACTIVENESS
12. CASE STUDY
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/fnd186
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900